oya99
Member
- Joined
- May 23, 2018
- Messages
- 15
- Reason
- CALS
- Diagnosis
- 03/2018
- Country
- US
- State
- LA
- City
- New Orleans
I would like to correct a misunderstanding here; the cost of NurOwn is NOT estimated to be $300K.
Earlier @Par220 posted an informative article which included the following quote:
"Lebovits declined to estimate the cost for NurOwn beyond saying that cost of manufacturing and delivering the therapy is similar to CAR T cancer therapies. Yescarta, a CAR T therapy from the Kite Pharma Inc. unit of Gilead Sciences Inc., has a wholesale acquisition cost (WAC) of $373,000."
1. This is a different therapy, not NurOwn. The CEO mentioned in passing that the cost would be similar, but he mentioned two different companies that are still not in production yet, and did not specifically mention Yescarta. Yescarta is an example picked by the article's author not the CEO.
2. The "wholesale acquisition cost" has not much to do with actual cost of production for a drug/treatment. $373K given is based on a drug that is not fully in production, it is provided on a limited basis. Once a drug goes into production, based on fixed costs there are a lot of economies of scale and the per unit production costs will decline dramatically.
3. This still does not tell us much about "pricing". As said, Brainstorm has been in operation since almost 2010 and it has large amount of costs to recover.
For all these reasons and many more, I do not think we should discuss pricing until there is clear information on the subject. Speculation will only lead to misinformation and will further upset readers.
Earlier @Par220 posted an informative article which included the following quote:
"Lebovits declined to estimate the cost for NurOwn beyond saying that cost of manufacturing and delivering the therapy is similar to CAR T cancer therapies. Yescarta, a CAR T therapy from the Kite Pharma Inc. unit of Gilead Sciences Inc., has a wholesale acquisition cost (WAC) of $373,000."
1. This is a different therapy, not NurOwn. The CEO mentioned in passing that the cost would be similar, but he mentioned two different companies that are still not in production yet, and did not specifically mention Yescarta. Yescarta is an example picked by the article's author not the CEO.
2. The "wholesale acquisition cost" has not much to do with actual cost of production for a drug/treatment. $373K given is based on a drug that is not fully in production, it is provided on a limited basis. Once a drug goes into production, based on fixed costs there are a lot of economies of scale and the per unit production costs will decline dramatically.
3. This still does not tell us much about "pricing". As said, Brainstorm has been in operation since almost 2010 and it has large amount of costs to recover.
For all these reasons and many more, I do not think we should discuss pricing until there is clear information on the subject. Speculation will only lead to misinformation and will further upset readers.